

Press release

Stockholm, May 3, 2017

Bactiguard appoints new distributor in Brazil

Bactiguard signs distribution agreement and enters partnership with Biodina for Brazil.

"Biodina has a very strong track record of successfully introducing new and advanced products on the Brazlian market and we are very happy to have them as our partner. We have not been satisfied with the development of Bactiguard sales in Brazil and we have therefore been searching for a new distributor since early this year. With Biodina we are certain that we have found what we are looking for.", says Christian Kinch, CEO.

"We are excited about the partnership with Bactiguard. Their innovative technology and products meet a clear need in the Brazilian market, particularly in light of increasing antibiotic resistance", says Edson Petrillo, General Manager of Biodina.

Brazil is the biggest market in Latin America and one of the most populous countries in the world with a population of over 200 million. Biodina is headquarted in Rio de Janeiro and has an extensive network of sales offices and sub-distributors covering all of Brazil.

The partnership will be kick-started with a joint marketing activity on May 4-5, when Bactiguard together with Biodina will be exhibiting at the Sepsis Forum in Sao Paolo.

For further information, please contact:

Johan Rugfelt, COO, cell phone: +46 708 724 739



About Bactiguard

Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission we develop and supply infection protection solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large. The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner CR Bard, urinary catheters with Bactiguard's coating are market leading in the USA and Japan. Bactiguard's own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.

Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. The company has about 60 employees around the world. Its headquarters and one of two production facilities are located in Stockholm, the other one in Malaysia. Bactiguard is listed on Nasdaq Stockholm.

Read more about how Bactiguard saves lives on www.bactiguard.com